The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib

(2018) Teemu P Miettinen et al.   EMBO JOURNAL

CDK8 regulates the angiogenesis of pancreatic cancer cells in part via the CDK8-β-catenin-KLF2 signal axis

(2018) Ran Wei et al.   EXPERIMENTAL CELL RESEARCH

p16, p21, and p53 proteins play an important role in development of pancreatic intraepithelial neoplastic

(2018) Justyna Zińczuk et al.   IRISH JOURNAL OF MEDICAL SCIENCE

Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy

(2018) Anna-Laura Kretz et al.   Cancers

Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer

(2018) Veronique Veenstra et al.   Cancers

Racial Disparity in Gastrointestinal Cancer Risk

(2017) Hassan Ashktorab et al.   GASTROENTEROLOGY

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer

(2017) Angela Chou et al.   GUT

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

(2017) Hanxiao Xu et al.   Journal of Hematology & Oncology

Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study

(2017) Robert de W. Marsh et al.   JOURNAL OF SURGICAL ONCOLOGY

CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells

(2017) Q Wang et al.   ONCOGENE

Tumor Heterogeneity in Pancreatic Adenocarcinoma

(2017) Jerome Cros et al.   PATHOBIOLOGY

CDK9 is a prognostic marker and therapeutic target in pancreatic cancer

(2017) Anna-Laura Kretz et al.   TUMOR BIOLOGY

Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma

(2017) Huai-Qiang Ju et al.   Nature Communications

PCTK3/CDK18 regulates cell migration and adhesion by negatively modulating FAK activity

(2017) Shinya Matsuda et al.   Scientific Reports

A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy

(2016) Farrukh T. Awan et al.   ANNALS OF HEMATOLOGY

A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties

(2016) Vikas Kumar et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Targeting CDK4/6 in patients with cancer

(2016) Erika Hamilton et al.   CANCER TREATMENT REVIEWS

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

(2016) Jonathan W. Goldman et al.   Clinical Lung Cancer

Current standards and new innovative approaches for treatment of pancreatic cancer

(2016) Thierry Conroy et al.   EUROPEAN JOURNAL OF CANCER

Systemic Chemotherapy in Advanced Pancreatic Cancer

(2016) Hee Seung Lee et al.   Gut and Liver

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms

(2016) Saswati Chand et al.   International Journal of Biological Sciences

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human CDK18 promotes replication stress signaling and genome stability

(2016) Giancarlo Barone et al.   NUCLEIC ACIDS RESEARCH

Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites

(2016) Robert J. Allaway et al.   Oncotarget

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

(2016) Jorge Franco et al.   Cell Reports

Pancreatic cancer

(2016) Jorg Kleeff et al.   Nature Reviews Disease Primers

Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway

(2015) Wei Xu et al.   CANCER LETTERS

Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors

(2015) Nawal Bendris et al.   CELL CYCLE

A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma

(2015) Ryan D. Cassaday et al.   Clinical Lymphoma Myeloma & Leukemia

Cyclin E Deregulation Promotes Loss of Specific Genomic Regions

(2015) Leonardo K. Teixeira et al.   CURRENT BIOLOGY

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

(2015) Zahi Mitri et al.   INVESTIGATIONAL NEW DRUGS

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer

(2015) Janice Lu   Journal of Hematology & Oncology

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

(2015) J Flynn et al.   LEUKEMIA

Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models

(2015) C. Hu et al.   MOLECULAR CANCER THERAPEUTICS

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNA polymerase II-associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II

(2015) M. Yu et al.   SCIENCE

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer

(2015) Agnieszka K. Witkiewicz et al.   Oncotarget

Loss of p27Kip1 promotes metaplasia in the pancreas via the regulation of Sox9 expression

(2015) Pauline Jeannot et al.   Oncotarget

Modelling the CDK-dependent transcription cycle in fission yeast: Figure 1

(2015) Miriam Sansó et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

(2015) Jorge Franco et al.   Oncotarget

ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34

(2014) Mi Hee Park et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers

(2014) A. M. Heilmann et al.   CANCER RESEARCH

The complex landscape of pancreatic cancer metabolism

(2014) C. M. Sousa et al.   CARCINOGENESIS

Pancreatic cancer genomics

(2014) David K Chang et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

(2014) Lawrence M. Gelbert et al.   INVESTIGATIONAL NEW DRUGS

KRAS: feeding pancreatic cancer proliferation

(2014) Kirsten L. Bryant et al.   TRENDS IN BIOCHEMICAL SCIENCES

Therapeutic options for the management of pancreatic cancer

(2014) Maria L Rossi   WORLD JOURNAL OF GASTROENTEROLOGY

CDK1 plays an important role in the maintenance of pluripotency and genomic stability in human pluripotent stem cells

(2014) I Neganova et al.   Cell Death & Disease

Cyclin D activates the Rb tumor suppressor by mono-phosphorylation

(2014) Anil M Narasimha et al.   eLife

Cyclin-dependent kinases

(2014) Marcos Malumbres   GENOME BIOLOGY

The two faces of Cdk8, a positive/negative regulator of transcription

(2013) Josipa Nemet et al.   BIOCHIMIE

Cyclin I is involved in the regulation of cell cycle progression

(2013) Taiki Nagano et al.   CELL CYCLE

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

(2013) Monica M. Mita et al.   Clinical Breast Cancer

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

(2013) J. Rader et al.   CLINICAL CANCER RESEARCH

Chk1 Inhibits E2F6 Repressor Function in Response to Replication Stress to Maintain Cell-Cycle Transcription

(2013) Cosetta Bertoli et al.   CURRENT BIOLOGY

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

(2013) John J Nemunaitis et al.   Journal of Translational Medicine

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

(2013) Joe J. Stephenson et al.   LUNG CANCER

The Molecular Balancing Act of p16 INK4a in Cancer and Aging

(2013) Kyle M. LaPak et al.   MOLECULAR CANCER RESEARCH

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience

(2013) J. E. Faris et al.   ONCOLOGIST

CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome

(2013) V. J. Guen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The multitalented Mediator complex

(2013) Jonas O.P. Carlsten et al.   TRENDS IN BIOCHEMICAL SCIENCES

Re-thinking cell cycle regulators: the cross-talk with metabolism

(2013) Lluis Fajas   Frontiers in Oncology

Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4

(2012) X. Huang et al.   BLOOD

Orphan kinases turn eccentric

(2012) Petra Mikolcevic et al.   CELL CYCLE

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

(2012) J. J. Luke et al.   CLINICAL CANCER RESEARCH

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

(2012) Jeffry L. Dean et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

(2012) Krishna S. Gunturu et al.   MEDICAL ONCOLOGY

Interaction of Cyclin-Dependent Kinase 12/CrkRS with Cyclin K1 Is Required for the Phosphorylation of the C-Terminal Domain of RNA Polymerase II

(2012) S.- W. G. Cheng et al.   MOLECULAR AND CELLULAR BIOLOGY

CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis

(2012) D. Subramaniam et al.   MOLECULAR CANCER THERAPEUTICS

Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration

(2012) M. K. Diril et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cyclin K goes with Cdk12 and Cdk13

(2012) Jiri Kohoutek et al.   Cell Division

Driving the Cell Cycle Through Metabolism

(2011) Ling Cai et al.   Annual Review of Cell and Developmental Biology

The CDK9/Cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: A possible role in embryonic genome activation

(2011) Reza K Oqani et al.   BMC DEVELOPMENTAL BIOLOGY

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

(2011) Georg Feldmann et al.   CANCER BIOLOGY & THERAPY

Pancreatitis-Induced Inflammation Contributes to Pancreatic Cancer by Inhibiting Oncogene-Induced Senescence

(2011) Carmen Guerra et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Consorting kinases, end of destruction and birth of a spindle

(2011) Karen Crasta et al.   CELL CYCLE

Cyclin-Dependent Kinase 5 Is Amplified and Overexpressed in Pancreatic Cancer and Activated by Mutant K-Ras

(2011) J. P. Eggers et al.   CLINICAL CANCER RESEARCH

Identification of target genes for the CDK subunits of the Mediator complex

(2011) Taiki Tsutsui et al.   GENES TO CELLS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

(2011) Elias Assaf et al.   ONCOLOGY

Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma

(2010) Anthony P. Lam et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A role for Cdc48/p97 and Aurora B in controlling chromatin condensation during exit from mitosisThis paper is one of a selection of papers published in this special issue entitled 8th International Conference on AAA Proteins and has undergone the Journal's usual peer review process.

(2010) Hemmo Meyer et al.   Biochemistry and Cell Biology

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

(2010) Marta Puyol et al.   CANCER CELL

Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence

(2010) Agustin Chicas et al.   CANCER CELL

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

(2010) Mark A. Dickson et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1

(2010) B. Bartkowiak et al.   GENES & DEVELOPMENT

Activation of cyclin B1–Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis

(2010) Olivier Gavet et al.   JOURNAL OF CELL BIOLOGY

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

Ofatumumab

(2010) Bodi Zhang   mAbs

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

(2009) Rong Chen et al.   BLOOD

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

(2009) Andrew Conroy et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

(2009) D. Rathkopf et al.   CLINICAL CANCER RESEARCH

Cell Cycle Control of Wnt Receptor Activation

(2009) Gary Davidson et al.   DEVELOPMENTAL CELL

A Conserved Phosphorylation Site within the Forkhead Domain of FoxM1B Is Required for Its Activation by Cyclin-CDK1

(2009) Yi-Ju Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells

(2009) Paul T. Brinkkoetter et al.   JOURNAL OF CLINICAL INVESTIGATION

Cyclin-dependent kinases: a family portrait

(2009) Marcos Malumbres et al.   NATURE CELL BIOLOGY

A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer

(2009) Richard D. Carvajal et al.   PANCREATOLOGY

An Unusual Member of the Cdk Family: Cdk5

(2008) Fatema A. Dhariwala et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Characterization of Cyclin L1 and L2 Interactions with CDK11 and Splicing Factors

(2008) Pascal Loyer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activation of FoxM1 during G2 Requires Cyclin A/Cdk-Dependent Relief of Autorepression by the FoxM1 N-Terminal Domain

(2008) J. Laoukili et al.   MOLECULAR AND CELLULAR BIOLOGY

CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

(2008) Ron Firestein et al.   NATURE

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology

(2008) S WANG et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

CDK inhibitors in cancer therapy: what is next?

(2007) Marcos Malumbres et al.   TRENDS IN PHARMACOLOGICAL SCIENCES